UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 12, 2022

IsoPlexis Corporation

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-40894 (Commission 46-2179799

(IRS Employer Identification No.)

File Number) 35 NE Industrial Road, Branford, CT 06405

(Address of principal executive offices and zip code) (203) 208-4111

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) □ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) □ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trading	Name of each exchange
Title of each class	Symbol(s)	on which registered
Common Stock, par value \$0.001 per	ISO	The Nasdaq Stock Market LLC

share

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company 🗵

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

On September 12, 2022 at 4:50 p.m. Eastern Time, the Company is participating in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, New York. In connection with such presentation, the Company is posting an investor slide deck to its website at www.isoplexis.com, a copy of which is furnished herewith as Exhibit 99.1.

The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

 Exhibit No.
 IsoPlexis Investor Slides dated September 12, 2022

 104
 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Description

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ISOPLEXIS CORPORATION

Title:

Date: September 12, 2022

By:

/s/ John Strahley Name:

John Strahley Chief Financial Officer

•••• isoplexis

EMPOWERING LABS, CHANGING HUMAN HEALTH

September 2022

Disclaimer and Forward-Looking Statements


Forward-looking statements and other information

The presentation contains "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts or assurances of future performance latitude litigation is such forward-looking statements may include, without limitation, statements about (future operations, and assumptions regarding the future of its business, future planes and strategies and other ruture operations. Such forward-looking statements may include, without limitation, statements about (future operation, feasural context), strate "potential, "sexet, "initend," may," predict, "project, "target," operation, financial or operation, results, including its financial guidance, anticipated business levels, future earning, forward-looking statements because they contain words such as "anticipate," believe," "stimate," "expect," "intend," "may," "predict," "project, "target," "potential," "sex, "will," would," could," "continuit," "continuit," "continuit," "continuit," "continuit," "continuit," "continuit," and other words and terms of similar meaning, Forward-looking statements are and uncertainties, may of which may be beyond its control, lsoPlexis outines to ontained in this press release, hodding, energy in the archest in which isoPlexis and terms of similar meaning, Forward-looking statements are and uncomes may differ materially from those made in or suggested by the forward-looking statements contained in this press release, those results of development may not be indicative of results of development in subsequent periods. New factors emerge from the target use isoPlexis' and doutcomes to differ from those reflected in forward-looking statements in subsequent periods. New factors emerge to not the target and solution and target periods and technologies, competitive companies and technologies, and to iso places and iso pressons and target periods and technologies, competitive companies and technologies, and iso proste

Market, industry and Other Data This presentation includes estimates regarding market and industry data. Unless otherwise indicated, information concerning our industry and the markets in which we operate, including our general expectations, market position, market opportunity and market size, are based on our management's knowledge and experience in the markets in which we operate, together with currently evailable information obtained from various sources, including publicly available information, industry reports and publications, surveys, our customers, trade and business organizations and other contacts in the markets in which we operate. Certain information is based on management estimates, which have been derived from third party sources, as well as data from our internal research. In presenting this information, which is derived in part from management estimates based on such data and other similar sources and on our knowledge of and our experience to date in, the markets in which we operate. Market and industry data, which is derived in part from management estimates and beliefs, are subject to change and may be limited by the availability of raw data, the voluntary nature of the data gathering process and other initiations interent in any staticular subject to uncertainty and risk due to a variety of factors, including those described in "Risk Factors" and "Special Note Regarding Forward-Looking Statements" of the registration statement. These and other factors could cause results to differ materially from those expressed in the estimates made by third parties and by us.

Trademarks Each trademark, trade name or service mark of any other company appearing or incorporated by reference in this presentation belongs to its holder. We do not intend our use or display of other companies' trademarks, trade names or service marks to imply a relationship with, or endorsement or sponsorship of us by, such other companies.







Key Growth Initiatives Driving IsoPlexis

- Commercial Growth: Drive continued velocity of 254 instrument base & flexibility of applications, demonstrating ability to 'land and expand' with installed base, increasing 'razorblade' consumable percentage of revenue
- **Product Growth:** Enhance flexibility of IsoCode cell analysis & launch Codeplex product suite to appeal to two larger mainstream markets, with attractive differentiation vs. market leaders
- **Operations & Finance:** Expand consumables gross margin to 70%+ range, driving top-line impact & profitability. Continue company-wide OpEx efficiencies to conserve cash while driving path to more profitable growth

Proliferate Instruments, Drive "Razorblade" consumables





ᡥ iso**plex**is 5






ytokines / Output Proteins per Cell	30+	Few	New Dimension of Cell Behavior
Surface Marker per Cell	Multiple & increasing	Many	Adding ISO Flexibili
Ease of Cytokine Workflow	√		
Miniaturized System (<18 inches)	✓	*	Ease of Use of
nstrument Requires No Technician	✓		Instrument & Software
Informatics Requires No Technician	✓	*	









CodePlex Addresses Customer Pain Points vs. Status Quo



CHANGING WORKFORCE demanding more time away from the bench, ie. effortless workflows



COSTS MATTER Performance must be balanced with price & labor cost





RESULTS DRIVEN all labs need confidence to move forward, with gold standard proteomics




PRECIOUS SAMPLES samples, whether fresh or banked, are valuable & harder to access














What does CodePlex Deliver?

- 20 sample chambers per chip (80 per run) at launch
 - 30 sample chambers per chip (120 per run) in later '23
- 5 50 plex Assays
- <10uL sample per chamber
- < 30 min hands on time for assay set up
- </= 15% CVs (within a single chip and across chips)
- Built-in triplicate for each sample chamber
- Integrated Analysis Software
- Test menu value: Same instrument as IsoCode Chips



